Cart

“Exploratory Analyses of Efficacy Data From Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug Applications PDF” has been added to your cart. View cart

This article PDF is available for purchase only. PDFs are free for members! Become a member and save today

Remove item	Thumbnail image	Product	Price	Quantity	Subtotal
×		Association Between Enhanced Soluble CD40 Ligand and Proinflammatory and Prothrombotic States in Major Depressive Disorder: Pilot Observations on the Effects of Selective Serotonin Reuptake Inhibitor Therapy PDF	$40.00	Association Between Enhanced Soluble CD40 Ligand and Proinflammatory and Prothrombotic States in Major Depressive Disorder: Pilot Observations on the Effects of Selective Serotonin Reuptake Inhibitor Therapy PDF quantity	$40.00
×		Adjunctive Modafinil at Initiation of Treatment With a Selective Serotonin Reuptake Inhibitor Enhances the Degree and Onset of Therapeutic Effects in Patients With Major Depressive Disorder and Fatigue PDF	$40.00	Adjunctive Modafinil at Initiation of Treatment With a Selective Serotonin Reuptake Inhibitor Enhances the Degree and Onset of Therapeutic Effects in Patients With Major Depressive Disorder and Fatigue PDF quantity	$40.00
×		The "Doses" of Initial, Untreated Hallucinations and Delusions: A Proof-of-Concept Study of Enhanced Predictors of First-Episode Symptomatology and Functioning Relative to Duration of Untreated Psychosis PDF	$40.00	The "Doses" of Initial, Untreated Hallucinations and Delusions: A Proof-of-Concept Study of Enhanced Predictors of First-Episode Symptomatology and Functioning Relative to Duration of Untreated Psychosis PDF quantity	$40.00
×		A 3-Month, Randomized, Placebo-Controlled, Neuroleptic Discontinuation Study in 100 People With Dementia: The Neuropsychiatric Inventory Median Cutoff Is a Predictor of Clinical Outcome PDF	$40.00	A 3-Month, Randomized, Placebo-Controlled, Neuroleptic Discontinuation Study in 100 People With Dementia: The Neuropsychiatric Inventory Median Cutoff Is a Predictor of Clinical Outcome PDF quantity	$40.00
×		A Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Adjunctive Paroxetine in Panic Disorder Patients Unsuccessfully Treated With Cognitive-Behavioral Therapy Alone PDF	$40.00	A Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Adjunctive Paroxetine in Panic Disorder Patients Unsuccessfully Treated With Cognitive-Behavioral Therapy Alone PDF quantity	$40.00
×		Opening Doors to Recovery: A Randomized Controlled Trial of a Recovery-Oriented Community Navigation Service for Individuals With Serious Mental Illnesses and Repeated Hospitalizations PDF	$40.00	Opening Doors to Recovery: A Randomized Controlled Trial of a Recovery-Oriented Community Navigation Service for Individuals With Serious Mental Illnesses and Repeated Hospitalizations PDF quantity	$40.00
×		The DEMO Trial: A Randomized, Parallel-Group, Observer-Blinded Clinical Trial of Strength Versus Aerobic Versus Relaxation Training for Patients With Mild to Moderate Depression PDF	$40.00	The DEMO Trial: A Randomized, Parallel-Group, Observer-Blinded Clinical Trial of Strength Versus Aerobic Versus Relaxation Training for Patients With Mild to Moderate Depression PDF quantity	$40.00
×		Multisite, Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Trial to Evaluate the Efficacy of Buspirone as a Relapse-Prevention Treatment for Cocaine Dependence PDF	$40.00	Multisite, Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Trial to Evaluate the Efficacy of Buspirone as a Relapse-Prevention Treatment for Cocaine Dependence PDF quantity	$40.00
×		Prevalence, Correlates, and Comorbidity of Bipolar I Disorder and Axis I and II Disorders: Results From the National Epidemiologic Survey on Alcohol and Related Conditions PDF	$40.00	Prevalence, Correlates, and Comorbidity of Bipolar I Disorder and Axis I and II Disorders: Results From the National Epidemiologic Survey on Alcohol and Related Conditions PDF quantity	$40.00
×		Prevalence of Baseline Serum Glucose and Lipid Testing in Users of Second-Generation Antipsychotic Drugs: A Retrospective, Population-Based Study of Medicaid Claims Data PDF	$40.00	Prevalence of Baseline Serum Glucose and Lipid Testing in Users of Second-Generation Antipsychotic Drugs: A Retrospective, Population-Based Study of Medicaid Claims Data PDF quantity	$40.00
×		A Pragmatic Therapeutic Approach to Address the Attrition of Adolescents and Young Adults With Borderline Personality Disorder in Dialectical Behavior Therapy Programs PDF	$40.00	A Pragmatic Therapeutic Approach to Address the Attrition of Adolescents and Young Adults With Borderline Personality Disorder in Dialectical Behavior Therapy Programs PDF quantity	$40.00
×		Perspectives on Perinatal Depression Treatment: Perinatal Psychiatry: The Challenges of Making Rational Treatment Decisions at the Interface of Psychiatry and Obstetrics PDF	$40.00	Perspectives on Perinatal Depression Treatment: Perinatal Psychiatry: The Challenges of Making Rational Treatment Decisions at the Interface of Psychiatry and Obstetrics PDF quantity	$40.00
×		A 6-Month Follow-Up Study of Posttraumatic Stress and Anxiety/Depressive Symptoms in Korean Children After Direct or Indirect Exposure to a Single Incident of Trauma PDF	$40.00	A 6-Month Follow-Up Study of Posttraumatic Stress and Anxiety/Depressive Symptoms in Korean Children After Direct or Indirect Exposure to a Single Incident of Trauma PDF quantity	$40.00
×		Olanzapine in the Treatment of Apathy in Previously Depressed Participants Maintained With Selective Serotonin Reuptake Inhibitors: An Open-Label, Flexible-Dose Study PDF	$40.00	Olanzapine in the Treatment of Apathy in Previously Depressed Participants Maintained With Selective Serotonin Reuptake Inhibitors: An Open-Label, Flexible-Dose Study PDF quantity	$40.00
×		Exploratory Analyses of Efficacy Data From Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug Applications PDF	$40.00	Exploratory Analyses of Efficacy Data From Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug Applications PDF quantity	$40.00
Coupon:

Instead of purchasing individual articles, subscribe to our membership plan and get unlimited access to all article PDFs from both of our journals.

Cart totals

Subtotal	$600.00
Total	$600.00

Proceed to checkout